In pancreatic cancer, gene mutations in the KEAP1/NRF2 pathway are rare; however, NRF2 expression levels are high in over 93% of pancreatic adenocarcinomas [14]. This evidence concerns the gene NFE2L2 and pancreatic adenocarcinoma.